查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1939518

EVA输液袋市场按腔室类型、应用和最终用户划分，全球预测（2026-2032）

EVA Infusion Bags Market by Chamber Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年 EVA 输液袋市值为 2.6455 亿美元，预计到 2026 年将成长至 2.9402 亿美元，到 2032 年将达到 5.1243 亿美元，复合年增长率为 9.90%。

主要市场统计数据
基准年 2025 2.6455亿美元
预计年份：2026年 2.9402亿美元
预测年份：2032年 5.1243亿美元
复合年增长率 (%) 9.90%

对EVA输液袋的权威介绍为推动临床实践、法规环境和供应链趋势中的选择和创新提供了框架。

EVA输液袋已成为现代肠外营养治疗中日益重要的组成部分，它结合了材料科学的进步以及安全性、相容性和供应链稳定性等实际考虑。随着临床医生和采购团队寻求在化学惰性、易操作性和无菌性之间取得平衡，基于EVA的系统因其材料稳定性、灵活的生产过程以及与替代聚合物相比更低的析出物含量而持续受到关注。这些特性不仅在急诊医院环境中至关重要，在门诊和家庭输液场景中也同样重要，因为易操作性和储存稳定性会影响临床应用。

本文简要检验了技术创新、监管重点和不断变化的医疗服务模式如何重新定义输液袋产品策略和采购。

由于技术创新、监管趋严以及医疗模式重组，输液输送系统格局正在改变。在技​​术方面，材料科学的进步推动了EVA配方的发展，使其具有更优异的阻隔性能和更广泛的配方相容性，迫使製造商重新评估产品系列和生产投资。同时，供应商正在采用先进的灭菌方法和精密的品质分析技术，这些措施共同提高了产品合格标准，并降低了批间差异。

分析2025年关税对整个静脉输液袋价值链的策略性地域多角化、多元化和供应链韧性措施的影响

影响跨境贸易的政策决策直接影响医疗设备组件（包括输液袋）的供应链连续性、成本结构和采购选择。 2025年关税的实施改变了整个采购行业的成本核算方式，并引发了製造商和经销商的多项即时应变措施。一些供应商加快了区域产品认证和本地化进程，以降低关税波动带来的风险。另一些供应商则重新审视了供应商合同，寻求签订长期协议或将采购来源多元化，转向受影响贸易走廊以外的其他供应商。这些措施降低了对单一供应来源的依赖，提高了供应链的韧性，但也带来了过渡成本，并增加了供应商关係管理的复杂性。

透过综合分析，将腔室设计、临床环境、病患人口统计特征、体积细分和通路等因素纳入考量，进而解释产品选择因素。

要了解产品性能和商业性动态，需要从产品细分的观点，考虑设计、使用环境、患者群、包装容量和分销管道。腔室配置是关键的差异化因素。单腔室设计优先考虑简洁性和与标准解决方案的广泛相容性，而多腔室设计，包括双腔室、三腔室、四腔室或更多腔室配置，则能够实现组合药物配製、成分延迟混合或在单一包装内给药多种药物。因此，当临床通讯协定需要精确配製或分离以确保稳定性时，多腔室设计是更好选择。

区域洞察：美洲、欧洲、中东和非洲以及亚太地区之间的差异将如何影响监管策略、采购重点和分销模式

区域因素对全球输液袋市场的供应策略、监管应对措施和商业性重点有显着影响。在美洲地区，采购决策主要取决于供应商的可靠性、是否符合当地医疗设备法规以及与医院系统的整合程度。急诊护理需求仍然是核心驱动因素，同时，支持门诊输液计画以减轻住院患者的负担也日益受到重视。服务该地区的製造商通常会投资建造本地品质系统和物流中心，以满足严格的服务水准要求并快速回应医院网路的竞标。

对竞争定位进行策略性评估，重点在于技术差异化、服务整合、通路伙伴关係和永续性作为关​​键优势。

输液袋领域的竞争格局呈现出成熟企业与专注于材料科学和品质体系服务能力的敏捷型新兴企业的并存态势。领先的供应商凭藉检验的材料平台、可靠的萃取物和浸出物数据以及可扩展的生产基础设施脱颖而出，从而能够快速响应临床需求。对自动化和品质分析的策略性投资使製造商能够降低产品变异性并加强监管申报，从而为那些能够持续证明产品品质的公司创造竞争优势。

为供应商和买家提供切实可行的、影响深远的建议，以提升材料合格、社区韧性、门诊病人支援计画和永续性合规性。

产业领导者可以采取以下几项切实可行的措施来增强韧性、加快产品上市速度并满足不断变化的临床需求。首先，优先考虑严格的材料合格流程，将先进的萃取物和萃取物测试与实际应用相容性测试相结合。这有助于减少监管摩擦，并增强临床医生和采购相关人员的信心。其次，投资模组化製造和区域供应中心，以降低贸易中断的风险，同时保持柔软性，以便快速回应需求波动。第三，为门诊和家庭输液患者开发支援项目，包括简化的配药指南、给药辅助工具和远距训练模组，以提高非急性环境下的安全性和应用率。

我们采用透明严谨的调查方法，结合专家访谈、监管分析和技术文献综述，为我们的实用结论和建议提供了支持。

本分析整合了对临床采购主管、产品开发专业人员和分销合作伙伴的访谈，并系统性回顾了与输液容器和聚合物材料相关的监管指南和技术文献。主要资料收集着重于决策者在急诊、门诊和居家照护环境中的优先事项（产品处理偏好、文件需求、采购标准等）。次要分析着重于已发布的法规结构、材料科学出版物以及关于医疗服务模式和供应链中断的趋势报告。

针对输液袋生态系统中寻求可持续竞争优势的利益相关人员，本文总结了技术、商业和营运方面的优先事项，并提出了简洁扼要的结论。

EVA输液袋在材料创新、临床需求和供应链现实的交汇点占据着策略性地位。日益严格的监管要求、向门诊和家庭输液的转变以及贸易中断等因素，都要求采用一种融合技术合格、供应链韧性和以客户为中心的服务的综合方法。能够展现严格的材料特性分析、可扩展的品质系统和灵活的物流能力的製造商，将更有能力满足不同医疗机构中临床医生的期望和采购标准。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第3章执行摘要

  • CXO观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新たな商机
  • 次世代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • ポーターの五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第5章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESGとサステナビリティ分析
  • ディスラプションとリスクシナリオ
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 按腔室类型分類的EVA输液袋市场

  • マルチチャンバー
    • 双腔体
    • クアッドチャンバー以上
    • 三腔体
  • 单室

9. 按应用分類的EVA输液袋市场

  • 成人
  • 新生
  • 儿童

第十章 EVA输液袋市场（以最终用户划分）

  • 门诊治疗
  • 诊所
  • 居家医疗
  • 医院

第十一章 EVA输液袋市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 EVA输液袋市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 EVA输液袋市场（按国家划分）

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

14. 美国EVA输液袋市场

第十五章：中国EVA输液袋市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Fresenius Kabi AG
  • Hemedis GmbH
  • ICU Medical, Inc.
  • Medline Industries, LP
  • Nanjing Tianxin Pharmaceutical Sci & Tech Development Co., Ltd.
  • Nipro Corporation
  • Poly Medicure Limited
  • Terumo Corporation
  • Valmed SRL
  • Weigao Group Medical Polymer Co., Ltd.
Product Code: MRR-9A6A6F2977F5

The EVA Infusion Bags Market was valued at USD 264.55 million in 2025 and is projected to grow to USD 294.02 million in 2026, with a CAGR of 9.90%, reaching USD 512.43 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 264.55 million
Estimated Year [2026] USD 294.02 million
Forecast Year [2032] USD 512.43 million
CAGR (%) 9.90%

An authoritative introduction that frames EVA infusion bags within clinical, regulatory, and supply chain dynamics driving selection and innovation

EVA infusion bags are an increasingly prominent component of contemporary parenteral therapy, combining material science advances with practical considerations around safety, compatibility, and supply chain resilience. As clinicians and procurement teams seek solutions that balance chemical inertness, ease of handling, and sterile integrity, EVA-based systems continue to attract attention for their material consistency, flexible manufacturing pathways, and potential to reduce leachables relative to alternative polymers. These attributes matter not only in acute care hospital settings but also across ambulatory and home infusion scenarios where handling ease and storage stability influence clinical adoption.

Concurrently, industry stakeholders are navigating converging pressures from regulatory scrutiny, sustainability commitments, and changing care delivery models. Regulators have sharpened expectations for container-closure system testing and extractables and leachables characterization, prompting manufacturers to refine material selection and qualification protocols. Meanwhile, the shift toward outpatient infusion and home healthcare increases demand for packaging formats that are robust, lightweight, and user-friendly, while distributors and pharmacies prioritize predictable shelf life and cold-chain compatibility where relevant. Taken together, these dynamics set the context for product innovation, procurement strategy evolution, and competitive differentiation across the infusion bag landscape.

A concise examination of how technological advances, regulatory focus, and shifting care delivery models are redefining infusion bag product strategy and procurement

The landscape for infusion delivery systems is undergoing transformative shifts driven by technology, regulatory emphasis, and care model reconfiguration. On the technology front, material science improvements have produced EVA formulations that exhibit improved barrier properties and compatibility with a wider range of formulations, prompting manufacturers to reassess product portfolios and manufacturing investments. In parallel, suppliers are adopting advanced sterilization approaches and enhanced quality analytics, which together raise the baseline for product qualification and reduce variability across batches.

Regulatory agencies are placing greater emphasis on container-closure integrity and the rigorous assessment of extractables and leachables, which changes the development timelines and documentation requirements for new product introductions. These regulatory shifts incentivize firms to invest in standardized testing frameworks and more transparent data packages, promoting long-term trust with healthcare purchasers. At the same time, the care delivery environment is moving toward decentralized models; outpatient infusion clinics, home healthcare programs, and ambulatory services are expanding, and they require products that simplify handling, reduce preparation time, and support safe administration by non-specialist caregivers. Collectively, these shifts are reshaping supplier strategies, accelerating consolidation in some value chain segments, and opening opportunities for device differentiation through both material and service propositions.

An informed analysis of how recent tariff measures in 2025 triggered strategic regionalization, diversification, and supply chain resilience measures across the infusion bag value chain

Policy decisions that affect cross-border trade have direct implications for supply chain continuity, cost structures, and sourcing choices for medical device components, including infusion bags. The imposition of tariffs in 2025 altered cost calculus across procurement teams and prompted several immediate responses from manufacturers and distributors. Some suppliers accelerated regional qualification and localization efforts to reduce exposure to tariff volatility, while others revisited supplier agreements, seeking longer-term contracts or diversification to alternative suppliers outside affected trade corridors. These actions reduced single-source dependencies and improved resilience, but they also introduced transition costs and complexity into supplier relationship management.

Importantly, healthcare purchasers responded by updating total-cost evaluations to include tariff-driven landed cost fluctuations and by prioritizing suppliers with transparent sourcing and distribution footprints. Regulatory compliance and product equivalency remained primary selection criteria, yet procurement teams increasingly valued robust logistics assurances, predictable lead times, and secondary sourcing options. To mitigate future trade-related disruptions, several manufacturers expanded inventory buffers and negotiated forward-looking supply agreements, balancing risk tolerance against working capital impacts. Overall, the 2025 tariff environment accelerated strategic decisions around regionalization, supplier diversification, and operational contingency planning across the infusion bag ecosystem.

A comprehensive segmentation insight that integrates chamber design, care settings, patient application, capacity tiers, and distribution pathways to explain product selection drivers

Understanding product performance and commercial dynamics requires a segmentation lens that reflects design, use setting, patient population, packaging capacity, and distribution pathways. Chamber architecture is a central differentiator: single chamber designs prioritize simplicity and broad compatibility for standard fluids, while multi chamber formats-spanning dual, triple, and quad or higher chamber configurations-enable co-formulation, delayed mixing of components, or multi-drug administration in a single package, and thus are selected when clinical protocols demand precision or stability-preserving separation.

End-user context influences product selection and handling requirements. Hospitals typically demand high-volume formats and standardized compatibility with infusion devices, ambulatory care and clinic settings balance portability with sterility assurances, and home healthcare prioritizes intuitive design, clear labeling, and low preparation burden to support non-professional caregivers. Application-driven differences also shape requirements; adult formulations often necessitate larger capacities and robust compatibility testing, while neonatal and pediatric applications emphasize low dead space, precise dosing, and materials that minimize extractables relative to vulnerable patient populations. Capacity considerations-ranging from small-volume options up to 100 ml through mid-range 101-500 ml and larger greater-than-500 ml formats-determine packaging footprint, dosing strategies, and storage conditions. Finally, distribution pathways influence commercial dynamics: distributors and hospital pharmacies manage bulk procurement and inventory rotation, retail and online pharmacies prioritize point-of-care availability and consumer-facing labeling, and each channel imposes distinct regulatory and logistical requirements that manufacturers must address through packaging, documentation, and service-level commitments.

A regional insight that maps how Americas, Europe Middle East & Africa, and Asia-Pacific differences shape regulatory strategy, procurement priorities, and distribution models

Regional considerations materially influence supply strategies, regulatory alignment, and commercial priorities across the global infusion bag landscape. In the Americas, procurement decision-making emphasizes supplier reliability, compliance with local device regulations, and integration with hospital systems; acute care demand remains a core driver, and there is growing interest in support for outpatient infusion programs that reduce inpatient burdens. Manufacturers serving this region often invest in local quality systems and logistics hubs to meet tight service-level expectations and to respond quickly to hospital network tenders.

Europe, Middle East & Africa presents a heterogeneous regulatory and procurement environment that rewards flexible supply models and comprehensive technical dossiers. Diverse reimbursement models and national regulatory regimes require adaptable market access strategies and robust clinical evidence packages. The region also shows a rising appetite for sustainability considerations in packaging and supply operations, which influences supplier selection. In Asia-Pacific, rapid expansion of healthcare infrastructure, increased capacity in hospital networks, and growth in home healthcare services create demand for a wide range of capacities and chamber formats. Producers targeting this region often combine competitive manufacturing economics with investments in local regulatory support and distribution partnerships to accelerate adoption. Across all regions, alignment between product attributes and local care models, combined with transparent supply assurances, remains fundamental to commercial success.

A strategic review of competitive positioning that highlights technical differentiation, service integration, channel partnerships, and sustainability as key advantages

Competitive dynamics in the infusion bag sector reflect a mix of legacy incumbents and agile innovators that emphasize material science, quality systems, and service capabilities. Leading suppliers differentiate through validated material platforms, robust extractables and leachables data, and scalable manufacturing footprints that support rapid response to clinical demand. Strategic investments in automation and quality analytics enable manufacturers to reduce variability and strengthen regulatory submissions, creating a competitive moat for those firms that can consistently demonstrate product integrity.

Other firms compete by focusing on end-to-end service offerings, providing sterile filling, customized porting or connector options, and integrated traceability that supports hospital inventory management. Partnerships between device producers and specialty distributors have widened market reach, allowing smaller manufacturers to access large purchasing networks and complex channel requirements. Additionally, companies that prioritize sustainability-through reduced packaging waste, recyclable components, or energy-efficient manufacturing-are beginning to gain preference among healthcare systems that incorporate environmental criteria into procurement. Taken together, these strategic postures-technical differentiation, service integration, channel partnerships, and sustainability leadership-define the competitive contours and create multiple pathways to commercial advantage.

Practical and high-impact recommendations for suppliers and purchasers to enhance material qualification, regional resilience, outpatient support programs, and sustainability alignment

Industry leaders can take several pragmatic actions to strengthen resilience, accelerate product adoption, and meet evolving clinical requirements. First, prioritize a rigorous material qualification pathway that couples advanced extractables and leachables testing with real-world compatibility studies; this reduces regulatory friction and increases confidence among clinician and procurement stakeholders. Second, invest in modular manufacturing and regional supply hubs to limit exposure to trade disruptions while preserving flexibility for rapid scale-up in response to demand shifts. Third, develop targeted support programs for outpatient and home infusion customers, including simplified preparation guides, dosing aids, and remote training modules to improve safety and adoption in non-acute settings.

Moreover, align commercial proposals with sustainability initiatives by optimizing packaging and exploring recyclable or lower-impact materials, thereby meeting growing institutional priorities. Strengthen distribution relationships through clear service-level agreements and digital traceability to enhance inventory visibility and reduce stockouts. Finally, embed flexible contracting options and contingency clauses that permit rapid supplier substitution or volume reallocation, balancing operational resilience with financial discipline. These combined moves will help manufacturers and distributors navigate current uncertainties while positioning for longer-term growth in diversified care settings.

A transparent and rigorous methodology combining expert interviews, regulatory analysis, and technical literature review to underpin practical conclusions and recommendations

This analysis synthesizes primary interviews with clinical procurement leaders, product development specialists, and distribution partners, combined with a structured review of regulatory guidance and technical literature relevant to infusion containers and polymeric materials. Primary data collection emphasized decision-maker priorities across acute, ambulatory, and home care settings, including product handling preferences, documentation needs, and procurement criteria. Secondary analysis focused on publicly available regulatory frameworks, material science publications, and trend reporting related to healthcare delivery models and supply chain disruptions.

The approach triangulated qualitative insights from subject matter experts with document-based evidence to ensure that recommendations are grounded in practice and regulation. Emphasis was placed on cross-validating claims about material performance and handling with practitioners who evaluate these products daily. Limitations include variability in national regulatory interpretations and the ongoing evolution of decentralized care programs, which require continuous monitoring. To mitigate these limits, the methodology incorporated sensitivity checks and scenario-based discussion to reflect a range of plausible operational responses and strategic choices.

A concise conclusion that synthesizes technical, commercial, and operational priorities for stakeholders seeking durable advantage in the infusion bag ecosystem

EVA infusion bags occupy a strategic position at the intersection of material innovation, clinical needs, and supply chain realities. The confluence of stricter regulatory expectations, shifts toward outpatient and home-based infusion, and trade-driven disruptions necessitates an integrated approach that blends technical qualification with supply resilience and customer-centric services. Manufacturers that can demonstrate rigorous material characterization, scalable quality systems, and responsive logistics will be best positioned to meet clinician expectations and procurement thresholds across diverse care settings.

Equally, purchasers and healthcare organizations should emphasize supplier transparency, multi-source strategies, and alignment with sustainability commitments when updating procurement frameworks. The evolving landscape creates opportunities for differentiation through modular product design, targeted channel strategies, and enhanced post-market support that together increase adoption and patient safety. In sum, the sector's immediate priorities involve strengthening technical validation, diversifying supply footprints, and elevating service models to match the demands of modern care delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. EVA Infusion Bags Market, by Chamber Type

  • 8.1. Multi Chamber
    • 8.1.1. Dual Chamber
    • 8.1.2. Quad Chamber And Above
    • 8.1.3. Triple Chamber
  • 8.2. Single Chamber

9. EVA Infusion Bags Market, by Application

  • 9.1. Adult
  • 9.2. Neonatal
  • 9.3. Pediatric

10. EVA Infusion Bags Market, by End User

  • 10.1. Ambulatory Care
  • 10.2. Clinic
  • 10.3. Home Healthcare
  • 10.4. Hospital

11. EVA Infusion Bags Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. EVA Infusion Bags Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. EVA Infusion Bags Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States EVA Infusion Bags Market

15. China EVA Infusion Bags Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. B. Braun Melsungen AG
  • 16.6. Baxter International Inc.
  • 16.7. Fresenius Kabi AG
  • 16.8. Hemedis GmbH
  • 16.9. ICU Medical, Inc.
  • 16.10. Medline Industries, LP
  • 16.11. Nanjing Tianxin Pharmaceutical Sci & Tech Development Co., Ltd.
  • 16.12. Nipro Corporation
  • 16.13. Poly Medicure Limited
  • 16.14. Terumo Corporation
  • 16.15. Valmed S.R.L.
  • 16.16. Weigao Group Medical Polymer Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL EVA INFUSION BAGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EVA INFUSION BAGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EVA INFUSION BAGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES EVA INFUSION BAGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA EVA INFUSION BAGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EVA INFUSION BAGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY DUAL CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY DUAL CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY DUAL CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY QUAD CHAMBER AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY QUAD CHAMBER AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY QUAD CHAMBER AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY TRIPLE CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY TRIPLE CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY TRIPLE CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY SINGLE CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY SINGLE CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY SINGLE CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY NEONATAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY NEONATAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY NEONATAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS EVA INFUSION BAGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA EVA INFUSION BAGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. MIDDLE EAST EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASEAN EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GCC EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GCC EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. GCC EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 92. GCC EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. GCC EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPEAN UNION EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. BRICS EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. G7 EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. G7 EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. G7 EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 107. G7 EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. G7 EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NATO EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NATO EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NATO EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 112. NATO EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. NATO EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES EVA INFUSION BAGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. UNITED STATES EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA EVA INFUSION BAGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. CHINA EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)